Which drug is most appropriate for the treatment of acute DVT in a patient requiring oral therapy?

Rivaroxaban is an appropriate choice for the treatment of acute deep vein thrombosis (DVT) for patients who require oral therapy. It belongs to a class of medications known as direct oral anticoagulants (DOACs). Rivaroxaban directly inhibits Factor Xa, an essential component in the coagulation cascade that leads to clot formation. This mechanism provides effective and rapid anticoagulation, which is crucial in the management of acute DVT.

One significant advantage of rivaroxaban is its oral administration route, which offers convenience and improves patient compliance when compared to parenteral therapies. This is particularly important in outpatient settings or for patients who might have difficulty with injections.

While other options may seem relevant, they do not align with the requirement for oral therapy or the specific context of acute DVT. Betrixaban, although also an oral anticoagulant, is typically used for prophylaxis rather than the initial treatment of acute DVT. Enoxaparin is a low molecular weight heparin often used in hospital settings for the acute treatment of DVT, but it requires injection rather than oral administration. Clopidogrel, an antiplatelet agent, is not suitable for the management of venous thromboembolism